Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition’s commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer’s disease. Pesa brings 25 years of pharmaceutical commercial leadership to Alpha Cognition. Jen has successfully launched 12 products across 13 therapeutic areas, including neurology, psychiatry, and in multiple geriatric markets. With 14 years dedicated to long-term care or LTC, she has a deep understanding of this complex segment and a proven track record in building strategies that improve patient outcomes while enhancing healthcare delivery. Her expertise in driving cross-functional collaboration across marketing, market access, and sales operations will be instrumental in establishing the commercial success of ZUNVEYL.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACOG:
- Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
- Alpha Cognition files to sell 1.45M common shares for holders
- Alpha Cognition Raises $52.8 Million in Stock Offering
- Alpha Cognition Reports Promising Data for Brain Injury Drug
- Alpha Cognition voluntarily delisting from Canadian Securities Exchange
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue